CDSCO Panel Rejects AbbVie's Clinical Trial Waiver Plea for Foslevodopa-Foscarbidopa Injection Written By Susmita Roy5 July 2026 11:45 AM ISTNew Delhi: Pharmaceutical major AbbVie Healthcare India Private Limited has failed to secure a complete clinical trial waiver from the Subject Expert...
Health Ministry Bans 16 FDCs Including Amoxicillin, Serratiopeptidase; See Full List Written By Susmita Roy20 Jun 2026 6:00 PM ISTNew Delhi: In a major regulatory action aimed at improving drug safety and promoting rational use of medicines, the Ministry of Health and Family...
Orbit of Care in Indian T2D with CV Risk: Practice Update & Spotlight on Smart Application of Dapagliflozin & Sitagliptin FDC Written By Dr Manoj Chawla4 Jun 2026 10:56 AM ISTIn India, type 2 diabetes(T2D) clusters with cardiovascular risk and earlier age than in Western populations, mainly driven by visceral adiposity...
Dapagliflozin-Metformin in Obese T2D After GLP-RA: Assessing Newer Possibilities- Dr Bharat Saboo Written By Dr Bharat Saboo26 May 2026 10:37 AM ISTGlobally and in India, T2DM prevalence continues to rise, with obesity as one of its most important clinical drivers, reported in nearly 60-90% of...
Delhi HC Upholds Ban on Unapproved FDC Drugs, Backs DCGI Action Written By Susmita Roy2 May 2026 7:30 PM ISTNew Delhi: The Delhi High Court has cleared the path for cancelling licences related to the manufacture, sale, marketing, and distribution of...
Dapagliflozin and Sitagliptin FDC in Indian T2D: 5 Points Clinicians May Like to Know - Dr K Baraneedharan Written By Dr. K. Baraneedharan9 April 2026 12:00 PM ISTThe burden of T2DM is increasing worldwide, with enormous implications for morbidity and mortality. Early and effective intervention is essential to...
Integrating Dapagliflozin and Sitagliptin FDC for Optimizing Outcomes in Type-2 Diabetes with Cardiometabolic-Based Chronic Disease (CMBCD) patients - Dr Kaushik Biswas Written By Dr. Kaushik Biswas28 March 2026 10:27 AM ISTIntroduction India's T2D population carries a substantial burden-nearly two-thirds of individuals with T2D are overweight or obese, indicating a...
SC Seeks Centre, DCGI Response on Micro Labs' Plea Against Anti-Diabetic FDC Ban Written By Susmita Roy26 Feb 2026 10:26 PM ISTNew Delhi: The Supreme Court sought responses from the Union government and the Drug Controller General of India regarding an appeal filed by Micro...
Empagliflozin & Sitagliptin - Landmark Trials Revisited in 2026 Written By Dr. Dheeraj Kapoor23 Feb 2026 10:30 AM ISTIn this episode of Diabetes Wellness Forum, titled, "Empagliflozin & Sitagliptin - Landmark Trials Revisited in 2026", Dr Nandita Mohan from...
DTAB Sub-Panel to Reassess 29 'Irrational' FDCs Flagged by Kokate Committee: Report Written By Susmita Roy17 Feb 2026 11:00 PM ISTNew Delhi: In a major move to strengthen drug safety and rational prescribing practices, regulators have initiated a renewed examination of 29...
Efficacy and Safety of Dapagliflozin-Vildagliptin in Indian T2DM Patients with CV Risk Factors Written By Dr. Nandita Mohan30 Jan 2026 12:58 PM ISTThe Fixed-Dose Combination (FDC) of Dapagliflozin 5 mg + Vildagliptin 50 mg demonstrated significant improvements in Glycemic Control, Metabolic...
Venus Remedies Secures Marketing Authorisation For Ceftazidime, Avibactam FDC In Indonesia Written By sheeba farhat15 Jan 2026 2:20 PM ISTThis approval represents Venus Remedies' first marketing authorization in the anti-infective segment in Indonesia and also enables the first generic...
